The company remains a pre-revenue entity with no commercialized products, reporting consistent quarterly operating losses that reached $14.6 million in 2024Q3.
| Metric | TTM | Sep'25 | Sep'24 | Sep'23 | Sep'22 | Sep'21 | Sep'20 | Sep'19 | Sep'18 | Sep'17 | Sep'16 | Sep'15 | Sep'14 | Sep'13 | Sep'12 | Sep'11 | Sep'10 | Sep'09 | Sep'08 | Sep'07 | Sep'06 | Sep'05 | Sep'04 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 44.6M | 51.41M | 52.88M | 55.76M | 50.99M | 42M | 30.94M | 28.81M | 19.18M | 15.54M | 14.88M | 7.11M | 2.97M | 2.13M | 4.32M | 6.18M | 5.64M | 4.73M | 5.27M | 1.58M | 25.59K | 91.54K | 14.47K |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 12.8M | 13.82M | 11.04M | 12.05M | 13.07M | 9.02M | 5.86M | 6.85M | 5.99M | 5.01M | 8.33M | 4.84M | 2.24M | 1.87M | 1.66M | 3.57M | 2.91M | 2.59M | 3.79M | 618.22K | 25.48K | 91.54K | 0 |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 31.8M | 37.59M | 41.84M | 43.72M | 37.92M | 32.98M | 25.23M | 22.26M | 13.34M | 10.67M | 7.25M | 2.27M | 732.39K | 263.85K | 2.65M | 2.6M | 2.73M | 2.14M | 1.48M | 959.7K | 0 | 0 | 0 |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 4.38M | 2.47M | 1.63M | 2.02M | 151.4K | 0 | 199.66K | -976.88K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -44.6M | -51.41M | -52.88M | -55.76M | -50.99M | -42M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.32M | -6.18M | -5.65M | 0 | -5.27M | -1.58M | -25.59K | -91.54K | 0 |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | 2.78% | 5.18% | -9.37% | -21.39% | - | - | - | - | - | - | - | - | 100% | 30.08% | -9.42% | - | 100% | -233.97% | -6065.93% | 72.04% | - | - |
| EBITDA | -38.87M | -46.38M | -43M | -46.54M | -47.62M | -37.64M | -31.06M | -28.88M | -19.13M | -15.57M | -15.04M | -12.11M | -11.59M | -2.14M | -4.32M | -6.18M | -5.65M | -4.03M | -5.27M | -1.58M | -25.65K | -91.67K | -14.47K |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | 24.6% | -7.85% | 7.6% | 2.27% | -26.51% | -21.17% | -7.56% | -50.94% | -22.92% | -3.51% | -24.23% | -4.42% | -442.55% | 50.53% | 30.09% | -9.41% | -40.28% | 23.6% | -233.69% | -6056.57% | 72.02% | -533.67% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.25K | 995 | 768 | 576 | 1.86K | 1.66K | 910 | 410 | 220 | 0 | 0 | 0 | 0 |
| EBIT | -38.87M | -46.38M | -43M | -46.54M | -47.62M | -37.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Interest Income | 4.36M | 4.68M | 7.32M | 5.55M | 947K | 26K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 4.36M | 4.68M | 7.32M | 6.52M | 947K | 26K | 179.97K | 207.28K | 255.09K | 88.1K | 11.32K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 964K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71.83K | 7.09K | 51.34K | 144.3K | 90.25K | 291.83K | 57.86K | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 4.67M | 5.03M | 9.88M | 8.26M | 3.37M | 4.36M | 4.5M | 2.54M | 1.58M | 2.05M | 164.16K | 70.55K | 232.7K | -1.51M | -3.84M | -1.04M | -2.85M | -707.63K | -9.77K | 1.24K | 59 | 125 | 0 |
| Pretax Income | -39.93M | -46.38M | -43M | -47.51M | -47.62M | -37.64M | -26.26M | -26.21M | -17.38M | -13.4M | -14.71M | -12.11M | -11.37M | -3.7M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 18K | 0 | 0 | 0 | 358K | 268K | 22.66K | 82.18K | 72.75K | 59.61K | 29.61K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.05% | 0% | 0% | 0% | -0.75% | -0.71% | -0.09% | -0.31% | -0.42% | -0.44% | -0.2% | 0% | 0% | 0% | - | - | - | - | - | - | - | - | - |
| Net Income | -39.95M | -46.38M | -43M | -47.51M | -47.98M | -37.91M | -26.28M | -26.29M | -17.45M | -13.46M | -14.74M | -12.11M | -11.37M | -3.7M | -8.3M | -7.31M | -8.78M | -5.5M | -5.35M | -1.58M | -25.53K | -91.63K | -14.39K |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | 14.08% | -7.85% | 9.48% | 0.99% | -26.56% | -44.25% | 0.06% | -50.66% | -29.66% | 8.66% | -21.71% | -6.51% | -207.25% | 55.43% | -13.61% | 16.8% | -59.71% | -2.77% | -238.69% | -6088.29% | 72.13% | -536.51% | - |
| Net Income (Continuing) | -39.95M | -46.38M | -43M | -47.51M | -47.98M | -37.91M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.45 | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 | -0.65 | -1.16 | -0.46 | -1.18 | -1.16 | -1.64 | -1.09 | -1.09 | -0.33 | -0.01 | -0.02 | -0.01 |
| EPS Growth % | 15.67% | -3.85% | 13.33% | 3.23% | -14.81% | -20% | 16.67% | -38.46% | -18.18% | 21.43% | 35.38% | 43.97% | -152.17% | 61.02% | -1.72% | 29.27% | -50.46% | 0% | -230.3% | - | 74.88% | - | - |
| EPS (Basic) | - | -0.54 | -0.52 | -0.60 | -0.62 | -0.54 | -0.45 | -0.54 | -0.39 | -0.33 | -0.42 | -0.65 | -1.16 | -0.46 | -1.18 | -1.16 | -1.64 | -1.09 | -1.09 | -0.33 | -0.01 | -0.02 | -0.01 |
| Diluted Shares Outstanding | 89.03M | 85.29M | 83.47M | 79.79M | 76.91M | 69.8M | 58.2M | 48.91M | 44.66M | 40.84M | 35.15M | 18.59M | 9.8M | 7.98M | 7.04M | 6.29M | 5.36M | 5.05M | 4.93M | 4.8M | 4.8M | 4.35M | 1.91M |
| Basic Shares Outstanding | 89.03M | 85.29M | 83.47M | 79.79M | 76.91M | 69.8M | 58.2M | 48.91M | 44.66M | 40.84M | 35.15M | 18.59M | 9.8M | 7.98M | 7.04M | 6.29M | 5.36M | 5.05M | 4.93M | 4.8M | 4.8M | 4.35M | 1.91M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Binary Clinical Trial Outcomes
As indicated by the company's financial disclosures, Anavex Life Sciences maintains a high-cost structure, with quarterly R&D expenditures fluctuating between $4.7 million and $11.8 million over the last ten quarters, reflecting the intensive capital requirements inherent in advancing its late-stage clinical pipeline toward potential regulatory milestones.
The company's cost structure is almost entirely dominated by R&D, which is typical for a pre-revenue biotechnology firm. Investors should monitor the volatility in these expenses, as they appear to correlate with the timing of clinical trial phases rather than a steady-state operational burn rate.
According to recent quarterly filings, Anavex consistently records stock-based compensation ranging from $1.1 million to $4.3 million per quarter, which serves to inflate the reported net loss while simultaneously contributing to the ongoing dilution of existing shareholders as the company funds its operations through equity-linked instruments.
The reliance on stock-based compensation as a primary tool for talent retention and operational funding warrants close scrutiny. This practice effectively shifts the cost of development from the income statement to the equity base, potentially obscuring the true economic cost of the company's research activities.
Based on the provided financial data, Anavex remains a pre-revenue entity with no commercialized products, meaning that all reported income statement figures reflect a continuous cycle of operational losses rather than any underlying growth trajectory in product sales or market penetration within the CNS therapeutic space.
The absence of revenue renders traditional growth metrics inapplicable, shifting the analytical focus entirely to the efficiency of capital deployment. Future revenue potential remains purely speculative and contingent upon successful regulatory outcomes for its lead candidates, blarcamesine and others in the pipeline.
As reported in financial statements, the company's persistent net losses, which reached $13.2 million in 2025Q3, highlight the significant risk that current cash reserves may prove insufficient to reach commercialization without further dilutive financing, especially if clinical trial timelines face unexpected regulatory delays or additional confirmatory requirements.
Short-sellers may focus on the company's inability to generate internal cash flow and its reliance on ATM facilities to sustain operations. This dependency creates a structural vulnerability where the company's valuation is perpetually tethered to its ability to access capital markets under potentially unfavorable conditions.
Quick answers to the most common questions about buying AVXL stock.
For fiscal year 2025, Anavex Life Sciences Corp. (AVXL) reported total revenue of $0.0M.
Anavex Life Sciences Corp. (AVXL) reported a net loss of $46.4M for the fiscal year ending 2025.